Evoke Shares Skyrocket On New FDA Market Exclusivity For Gimoti Nasal Spray

• The FDA has granted new drug product exclusivity to Evoke Pharma Inc's (NASDAQ: EVOK) Gimoti (metoclopramide) nasal spray to relieve symptoms associated with acute and recurrent diabetic gastroparesis in adults.

• Evoke now has exclusive marketing rights over three (3) years from the original date of approval under the Hatch-Waxman Act to protect the product from generic drug competition.

• In addition to the market exclusivity, Evoke maintains a robust patent estate, with currently two Orange book-listed patents that expire in 2029 and 2030.

• The Company has also been granted gender-specific patents in the EU, Japan, and Mexico until 2032.

• Furthermore, if approved, Evoke has other pending patent applications with individual expiration dates of 2032, 2037, and 2038.

• Price Action: EVOK shares are up 159.2% at $1.02 during the premarket session on the last check Tuesday.

See more from Benzinga

• EXCLUSIVE: SinglePoint Buys This Full-Service EPC Firm With Projected Revenue Of M

• Biden Administration Reverses Trump's Effort To Open More Land For Oil Drilling In Arctic: CNBC

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.